11 results returned.
Page of 1
Federal Trade Commission v. Shire ViroPharma Inc.
District Court: District of Delaware Status: Decided
On February 7, 2017, the FTC filed a complaint against Shire ViroPharma, alleging that the pharmaceutical company engaged in unfair method of competition and violated …
Shire US, Inc. v. Allergan, Inc. et al.
District Court: District of New Jersey Status: Pending
On October 2, 2017, Shire filed a complaint in New Jersey district court accusing Allergan of violating federal and state antitrust laws by improperly discounting …
In re: Suboxone Antitrust Litigation (State of Wisconsin, et al. v. Indivior Inc, et al.)
District Court: E.D. Pennsylvania Status: Pending
In September 2016, 35 state attorneys general and the District of Columbia brought a multi-district case against pharmaceutical manufacturer Indivior, MonoSol RX et al., alleging …
In re: EPIPEN (Epinephrine Injection, USP) Marketing, Sales Practices, and Antitrust Litigtion
District Court: District of Kansas Status: Pending
The plaintiffs in the case allege Mylan N.V. created and exploited an EpiPen monopoly by providing aggressive rebates and incentives to pharmacy benefit managers to …
In the Matter of Impax Laboratories Inc.
District Court: Federal Trade Commission Status: Pending
The Federal Trade Commission sued generic drugmaker Impax Laboratories Inc. for allegedly accepting more than $100 million to delay its release of a generic version …
Federal Trade Commission v. AbbVie Inc. et al.
District Court: Eastern District of Pennsylvania Status: Decided
FTC alleged AbbVie sued generic companies for patent infringement over their proposed generic version of the testosterone gel, AndroGel, without justifiable grounds but merely to …
Drogueria Betances LLC v. Novartis Pharmaceuticals Corp.
District Court: Southern District of New York Status: Pending
Novartis Pharmaceuticals Corp. allegedly agreed with Par Pharmaceuticals Inc. to squelch generic competition to Novartis’s hypertension drug Exforge, resulting in buyers paying millions more than …
Walgreen Co. et al v. Allergan, Inc
District Court: Eastern District of New York Status: Pending
Four drug retailers, including Walgreens and Albertsons, filed an antitrust suit alleging that Allergan devised and carried out a multifaceted and anticompetitive scheme to maintain …
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al.
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of …
Federal Trade Commission v. Actavis, Inc.
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims …
In re: Flonase Antitrust Litigation
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline …
11 results returned.
Page of 1